With Gilead Sciences Inc. posting strong, even "record" sales of its HIV drug franchise for the second quarter, and launching the first of two Phase III studies of promising once-daily, HIV integrase inhibitor elvitegravir, the Foster City, Calif.-based firm's quarterly progress should have sounded like music to investors' ears. (BioWorld Financial Watch) Read More
